Study 10 of 25 for search of: "Peritonitis"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive Tract
This study is currently recruiting participants.
Verified by Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group, August 2007
Sponsored by: Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Information provided by: Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
ClinicalTrials.gov Identifier: NCT00511212
  Purpose

The purpose of this study is to assess the clinical usefulness of IVIG in combination therapy with antibacterial agents for severe peritonitis after lower digestive tract surgery.


Condition Intervention
Peritonitis
Postoperative Complications
Drug: intravenous immunoglobulin

MedlinePlus related topics: Antibiotics
Drug Information available for: Immunoglobulins Globulin, Immune
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Clinical Study of Intravenous Immunoglobulin (IVIG) in Combination Therapy With Antibacterial Agents for Surgical Site Infection of the Lower Digestive Tract

Further study details as provided by Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group:

Primary Outcome Measures:
  • clinical efficacy [ Time Frame: at day 7 ]

Secondary Outcome Measures:
  • clinical efficacy, recurrence rate, mortality, time between drug administration and defervescence, defervescence rate,time between drug administration and disappearance of clinical symptoms, improvement rate on clinical symptoms [ Time Frame: at day 3 and at the end of test drug administration, ]

Estimated Enrollment: 60
Study Start Date: August 2007
Estimated Study Completion Date: June 2009
  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients who have obvious symptoms and observation of post-surgical peritonitis, and meet the criteria described bellow.

  1. Patients with >=38 degrees C, >=15,000/mm3 or <=3,000/mm3 of WBC and >=10mg/dL of CRP
  2. Patients who have no abscess on the abdominal image
  3. Patients who were administered antibacterial agents for 1 day or more, and show no sign of improvement
  4. Patients who are 20 years old or older
  5. Patients who have signed the agreement for participation in this study

Exclusion Criteria:

  1. Patients who have a history of hypersensitivity to any of the ingredients of Immunoglobulin products
  2. Patients who have a history of shock due to any of the ingredients of Immunoglobulin products
  3. Patients who were administered immunoglobulin within 1 month before entry
  4. Patients who were administered antibacterial agents for 1 day or more, and show signs of improvement
  5. Patients with IgA deficiency
  6. Patients with hereditary fructose intolerance
  7. Patients with history of allergy or adverse effect for antibacterial agents
  8. Patients who have underlying or concomitant disease that may seriously affect the assessment of this study
  9. Patients who are or could be pregnant
  10. Patients who have noninfectious fever, fungal infection or viral illness
  11. Other patients who are judged to be inadequate to participate in this study by their physician
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00511212

Contacts
Contact: Mitsugu Sekimoto, MD, PhD +81-6-6879-3251 ext 3251 sekimoto@surg2.med.osaka-u.ac.jp
Contact: Masataka Ikeda, MD, PhD +81-6-6879-3251 ext 3251 mikeda@surg2.med.osaka-u.ac.jp

Locations
Japan, Osaka
Osaka University Hospital Recruiting
Suita, Osaka, Japan, 565-0871
Contact: Mitsugu Sekimoto, MD, PhD     +81-6-6879-3251 ext 3251     sekimoto@surg2.med.osaka-u.ac.jp    
Contact: Masataka Ikeda, MD, PhD     +81-6-6879-3251 ext 3251     mikeda@surg2.med.osaka-u.ac.jp    
Sponsors and Collaborators
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group
Investigators
Study Chair: Morito Monden, MD, PhD Multicenter Clinical Study Group of Osaka
  More Information

Study ID Numbers: MCSGO-0701
Study First Received: August 1, 2007
Last Updated: August 2, 2007
ClinicalTrials.gov Identifier: NCT00511212  
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group:
severe peritonitis
SSI
lower digestive tract surgery
Severe peritonitis after lower digestive tract surgery

Study placed in the following topic categories:
Antibodies
Digestive System Diseases
Postoperative Complications
Immunoglobulins, Intravenous
Peritonitis
Peritoneal Diseases
Rho(D) Immune Globulin
Immunoglobulins

Additional relevant MeSH terms:
Pathologic Processes
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009